| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 144, 70-81, Copyright © 1994 by American Society for Investigative Pathology
REGULAR ARTICLES |
TJ de Vries, PH Quax, M Denijn, KN Verrijp, JH Verheijen, HW Verspaget, UH Weidle, DJ Ruiter and GN van Muijen
Department of Pathology, University Hospital, Nijmegen, The Netherlands.
Degradation of the extracellular matrix and other tissue barriers by proteases like plasminogen activators (PAs) is a prerequisite for neoplastic growth and metastasis. Recently, we reported that highly metastatic behavior of human melanoma cells in nude mice correlates with urokinase-type PA (u-PA) expression and activity and with PA inhibitor type 1 and 2 (PAI-1, PAI-2) expression. Here we report on the occurrence of components of the PA system in the various stages of human melanoma tumor progression in situ. We studied the protein distribution on freshly frozen lesions of common nevocellular nevi (n = 25), dysplastic (= atypical) nevi (n = 16), early primary melanomas (n = 8), advanced primary melanomas (n = 11), and melanoma metastases (n = 17). Tissue-type PA was present in endothelial cells in all lesions, whereas in metastases it could be detected in tumor cells in a minority of the lesions. u-PA, its receptor, PAI-1, and PAI-2 could not be detected in benign and in early stages but appeared frequently in advanced primary melanoma and melanoma metastasis lesions. u-PA was detected in stromal cells and in tumor cells at the invasive front, the u-PA receptor and PAI-2 in tumor cells, and PAI-1 in the extracellular matrix surrounding tumor cells. Localization of the corresponding messenger RNAs and enzyme activities revealed a similar distribution. We conclude that plasminogen activation is a late event in melanoma tumor progression.
This article has been cited by other articles:
 |
|
 |
|
  V. Stepanova, T. Lebedeva, A. Kuo, S. Yarovoi, S. Tkachuk, S. Zaitsev, K. Bdeir, I. Dumler, M. S. Marks, Y. Parfyonova, et al. Nuclear translocation of urokinase-type plasminogen activator Blood, July 1, 2008; 112(1): 100 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Lester, M. Jo, V. Montel, S. Takimoto, and S. L. Gonias uPAR induces epithelial mesenchymal transition in hypoxic breast cancer cells J. Cell Biol., July 24, 2007; 178(3): 425 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A.-R. Higazi, F. Ajawi, S. Akkawi, E. Hess, A. Kuo, and D. B. Cines Regulation of the single-chain urokinase-urokinase receptor complex activity by plasminogen and fibrin: novel mechanism of fibrin specificity Blood, February 1, 2005; 105(3): 1021 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Trisciuoglio, A. Iervolino, A. Candiloro, G. Fibbi, M. Fanciulli, U. Zangemeister-Wittke, G. Zupi, and D. Del Bufalo bcl-2 Induction of Urokinase Plasminogen Activator Receptor Expression in Human Cancer Cells through Sp1 Activation: INVOLVEMENT OF ERK1/ERK2 ACTIVITY J. Biol. Chem., February 20, 2004; 279(8): 6737 - 6745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Brat, A. A. Castellano-Sanchez, S. B. Hunter, M. Pecot, C. Cohen, E. H. Hammond, S. N. Devi, B. Kaur, and E. G. Van Meir Pseudopalisades in Glioblastoma Are Hypoxic, Express Extracellular Matrix Proteases, and Are Formed by an Actively Migrating Cell Population Cancer Res., February 1, 2004; 64(3): 920 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Rofstad, H. Rasmussen, K. Galappathi, B. Mathiesen, K. Nilsen, and B. A. Graff Hypoxia Promotes Lymph Node Metastasis in Human Melanoma Xenografts by Up-Regulating the Urokinase-Type Plasminogen Activator Receptor Cancer Res., March 1, 2002; 62(6): 1847 - 1853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. dos Santos, R. Torensma, T. J. de Vries, M. W. J. Schreurs, D. R. H. de Bruijn, E. Kater-Baats, D. J. Ruiter, G. J. Adema, G. N. P. van Muijen, and A. G. van Kessel Heterogeneous Expression of the SSX Cancer/Testis Antigens in Human Melanoma Lesions and Cell Lines Cancer Res., March 1, 2000; 60(6): 1654 - 1662. [Abstract] [Full Text]
|
|
|
|
|
|
S. Madoiwa, N. Komatsu, J. Mimuro, K. Kimura, M. Matsuda, and Y. Sakata Developmental Expression of Plasminogen Activator Inhibitor-1 Associated With Thrombopoietin-Dependent Megakaryocytic Differentiation Blood, July 15, 1999; 94(2): 475 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Koopman, J. Slomp, A. C. W. de Bart, P. H. A. Quax, and J. H. Verheijen Mitogenic Effects of Urokinase on Melanoma Cells Are Independent of High Affinity Binding to the Urokinase Receptor J. Biol. Chem., December 11, 1998; 273(50): 33267 - 33272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Suzuki, Y Hayashi, Y Wang, T Nakamura, Y Morita, K Kawasaki, K Ohta, N Aoyama, S R Kim, H Itoh, et al. Urokinase type plasminogen activator receptor expression in colorectal neoplasms Gut, December 1, 1998; 43(6): 798 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A.-R. Higazi, K. Bdeir, E. Hiss, S. Arad, A. Kuo, I. Barghouti, and D. B. Cines Lysis of Plasma Clots by Urokinase-Soluble Urokinase Receptor Complexes Blood, September 15, 1998; 92(6): 2075 - 2083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Busso, V. Péclat, A. So, and A.-P. Sappino Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints Ann Rheum Dis, September 1, 1997; 56(9): 550 - 557. [Abstract] [Full Text]
|
|
|
|
|
|
J. L. Dickinson, E. J. Bates, A. Ferrante, and T. M. Antalis Plasminogen Activator Inhibitor Type 2 Inhibits Tumor Necrosis Factor alpha-induced Apoptosis J. Biol. Chem., November 17, 1995; 270(46): 27894 - 27904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.N. Raghunath, J. E. Tomaszewski, S. T. Brady, R. J. Caron, S. S. Okada, and E. S. Barnathan Plasminogen Activator System in Human Coronary Atherosclerosis Arterioscler. Thromb. Vasc. Biol., September 1, 1995; 15(9): 1432 - 1443. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
